Symposium “Integrating Research and Clinical Development in Ovarian Cancer“

Symposium “Integrating Research and Clinical Development in Ovarian Cancer“

10:00 Emerging immune therapies in OC, Jalid Sehouli, Berlin
10:25 Anti-angiogenic therapy in OC, Domenica Lorusso, Milano
10:50 PARP inhibitors in OC therapy, Philipp Harter, Essen
11:15 Coffee break
11:30 Promotion of metastasis by p53 gain-offunction mutations, Thorsten Stiewe, Marburg
11:55 p53 as target and integration of translational research in international multicenter clinical trials,
           Nicole Concin, Leuven
12:20 Lunch
13:30 Towards a global picture of the OC microenvironment, Rolf Müller, Marburg
13:55 Chemokines and chemokine receptors in OC, Holger Bronger, Munich
14:20 Role of microRNAs and stromal heterogeneity in OC, Fatima Mechta-Grigoriou, Paris
14.45 Coffee break
15:00 Role of the cytotoxicity receptor NKG2D in cancer immunosurveillance,
            Elke Pogge von Strandmann, Marburg
15:25 Defective HLA antigen expression in OC and its potential clinical relevance, Soldano Ferrone, Boston
15:30 Immunotherapy in OC: first clinical data. Florian Heitz, Essen
15:55 Concluding remarks

Persönliche Angaben